$Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis$
Código QR

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis

IntroductionSeveral maintenance therapies are available for treatment of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). The objective of this review was to assess the efficacy and safety of lenalidomide monotherapy in these patients.MethodsMEDLINE, EMBASE, and the Coc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jia Li, Jianpeng Zhou, Wei Guo, Xingtong Wang, Yangzhi Zhao, Ou Bai
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	diffuse large B-cell lymphoma lenalidomide monotherapy treatment outcome systematic review meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/948f2973e4f3437c8baa43709a547c33
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:948f2973e4f3437c8baa43709a547c33
record_format	dspace
spelling	oai:doaj.org-article:948f2973e4f3437c8baa43709a547c332021-12-02T09:46:51ZEfficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis2234-943X10.3389/fonc.2021.756728https://doaj.org/article/948f2973e4f3437c8baa43709a547c332021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.756728/fullhttps://doaj.org/toc/2234-943XIntroductionSeveral maintenance therapies are available for treatment of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). The objective of this review was to assess the efficacy and safety of lenalidomide monotherapy in these patients.MethodsMEDLINE, EMBASE, and the Cochrane Library databases were searched for publications up to April 7, 2021. Original studies that had information on lenalidomide monotherapy for DLBCL patients with R/R status were included. Meta-analyses of response rates, adverse events (AEs), overall survival (OS), and progression-free survival (PFS) were performed. The pooled event rates were calculated using a double arcsine transformation to stabilize the variances of the original proportions. Subgroup analysis was used to compare patients with different germinal center B-cell-like (GCB) phenotypes.ResultsWe included 11 publications that examined DLBCL patients with R/R status. These studies were published from 2008 to 2020. The cumulative objective response rate (ORR) for lenalidomide monotherapy was 0.33 (95% CI: 0.26, 0.40), and the ORR was better in patients with the non-GCB phenotype (0.50; 95% CI: 0.26, 0.74) than the GCB phenotype (0.06; 95% CI: 0.03, 0.11). The major serious treatment-related AEs were neutropenia, thrombocytopenia, respiratory disorders, anemia, and diarrhea. The median PFS ranged from 2.6 to 34 months and the median OS ranged from 7.8 to 37 months.ConclusionThis study provides evidence that lenalidomide monotherapy was active and tolerable in DLBCL patients with R/R status. Patients in the non-GCB subgroup had better responsiveness.Jia LiJianpeng ZhouWei GuoXingtong WangYangzhi ZhaoOu BaiFrontiers Media S.A.articlediffuse large B-cell lymphomalenalidomidemonotherapytreatment outcomesystematic reviewmeta-analysisNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diffuse large B-cell lymphoma lenalidomide monotherapy treatment outcome systematic review meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	diffuse large B-cell lymphoma lenalidomide monotherapy treatment outcome systematic review meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jia Li Jianpeng Zhou Wei Guo Xingtong Wang Yangzhi Zhao Ou Bai Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
description	IntroductionSeveral maintenance therapies are available for treatment of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). The objective of this review was to assess the efficacy and safety of lenalidomide monotherapy in these patients.MethodsMEDLINE, EMBASE, and the Cochrane Library databases were searched for publications up to April 7, 2021. Original studies that had information on lenalidomide monotherapy for DLBCL patients with R/R status were included. Meta-analyses of response rates, adverse events (AEs), overall survival (OS), and progression-free survival (PFS) were performed. The pooled event rates were calculated using a double arcsine transformation to stabilize the variances of the original proportions. Subgroup analysis was used to compare patients with different germinal center B-cell-like (GCB) phenotypes.ResultsWe included 11 publications that examined DLBCL patients with R/R status. These studies were published from 2008 to 2020. The cumulative objective response rate (ORR) for lenalidomide monotherapy was 0.33 (95% CI: 0.26, 0.40), and the ORR was better in patients with the non-GCB phenotype (0.50; 95% CI: 0.26, 0.74) than the GCB phenotype (0.06; 95% CI: 0.03, 0.11). The major serious treatment-related AEs were neutropenia, thrombocytopenia, respiratory disorders, anemia, and diarrhea. The median PFS ranged from 2.6 to 34 months and the median OS ranged from 7.8 to 37 months.ConclusionThis study provides evidence that lenalidomide monotherapy was active and tolerable in DLBCL patients with R/R status. Patients in the non-GCB subgroup had better responsiveness.
format	article
author	Jia Li Jianpeng Zhou Wei Guo Xingtong Wang Yangzhi Zhao Ou Bai
author_facet	Jia Li Jianpeng Zhou Wei Guo Xingtong Wang Yangzhi Zhao Ou Bai
author_sort	Jia Li
title	Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
title_short	Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
title_full	Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
title_fullStr	Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
title_full_unstemmed	Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
title_sort	efficacy and safety of lenalidomide monotherapy for relapsed/refractory diffuse large b cell lymphoma: systematic review and meta-analysis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/948f2973e4f3437c8baa43709a547c33
work_keys_str_mv	AT jiali efficacyandsafetyoflenalidomidemonotherapyforrelapsedrefractorydiffuselargebcelllymphomasystematicreviewandmetaanalysis AT jianpengzhou efficacyandsafetyoflenalidomidemonotherapyforrelapsedrefractorydiffuselargebcelllymphomasystematicreviewandmetaanalysis AT weiguo efficacyandsafetyoflenalidomidemonotherapyforrelapsedrefractorydiffuselargebcelllymphomasystematicreviewandmetaanalysis AT xingtongwang efficacyandsafetyoflenalidomidemonotherapyforrelapsedrefractorydiffuselargebcelllymphomasystematicreviewandmetaanalysis AT yangzhizhao efficacyandsafetyoflenalidomidemonotherapyforrelapsedrefractorydiffuselargebcelllymphomasystematicreviewandmetaanalysis AT oubai efficacyandsafetyoflenalidomidemonotherapyforrelapsedrefractorydiffuselargebcelllymphomasystematicreviewandmetaanalysis
_version_	1718398019087368192

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis

Ejemplares similares